Financial Counselors Inc. Sells 4,390 Shares of Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Financial Counselors Inc. trimmed its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 2.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 160,914 shares of the biopharmaceutical company’s stock after selling 4,390 shares during the quarter. Financial Counselors Inc.’s holdings in Bristol-Myers Squibb were worth $9,990,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 2.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock worth $22,827,000 after acquiring an additional 10,456 shares in the last quarter. Toronto Dominion Bank increased its position in Bristol-Myers Squibb by 19.1% during the 2nd quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock valued at $58,813,000 after buying an additional 170,360 shares in the last quarter. Aperio Group LLC increased its position in Bristol-Myers Squibb by 9.9% during the 3rd quarter. Aperio Group LLC now owns 928,404 shares of the biopharmaceutical company’s stock valued at $57,635,000 after buying an additional 83,708 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Bristol-Myers Squibb by 1.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock valued at $6,830,000 after buying an additional 2,323 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its position in Bristol-Myers Squibb by 1,748.8% during the 2nd quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 60,035 shares in the last quarter. 72.29% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb stock opened at $50.54 on Thursday. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. The stock has a market cap of $81.64 billion, a price-to-earnings ratio of 16.79, a PEG ratio of 1.39 and a beta of 0.98. Bristol-Myers Squibb Co has a fifty-two week low of $46.94 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, research analysts forecast that Bristol-Myers Squibb Co will post 3.87 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 3.17%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.

Several brokerages recently issued reports on BMY. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. Credit Suisse Group upped their target price on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. BMO Capital Markets reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research report on Sunday, July 22nd. Barclays upped their target price on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Friday, October 12th. Finally, William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $62.42.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: Find a Trading Strategy That Works

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply